[Toxicological and pharmacological studies on a new drug: pirfibrate (EL-466) (author's transl)].
D000014:Abnormalities, Drug-Induced; D000818:Animals; D002994:Clofibrate / Q000494:pharmacology; D002995:Clofibric Acid; D004036:Diet, Atherogenic; D004285:Dogs; D005260:Female; D005298:Fertility / Q000187:drug effects; D006949:Hyperlipidemias / Q000188:drug therapy / Q000662:veterinary; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000633:toxicity*; D007928:Lethal Dose 50; D008055:Lipids / Q000097:blood; D008297:Male; D051379:Mice; D011247:Pregnancy; D011422:Propionates / Q000494:pharmacology / Q000633:toxicity*; D011727:Pyridinolcarbamate / Q000494:pharmacology; D011817:Rabbits; D051381:Rats
D000960:Hypolipidemic Agents; D008055:Lipids; D011422:Propionates; D002995:Clofibric Acid; D011727:Pyridinolcarbamate; C028670:pirifibrate; D002994:Clofibrate
Toxicidad y propiedades farmacológicas de un nuevo fármaco hipolipidemiante: pirifibrate (EL-466).